Prognostic significance of a combination of novel biomarkers in the long-term stratification of adverse outcomes in patients with ST-segment elevation myocardial infarction

Prognostic significance of a combination of novel biomarkers in the long-term stratification of adverse outcomes in patients with ST-segment elevation myocardial infarction

A multi-marker approach for assessing the prognosis of patients with ST-segment elevation myocardial infarction (STEMI) is a promising strategy.Aim. To assess the potential prognostic power of soluble growth stimulation gene-2 (sST2), pentraxin 3 (PTX3), and N-terminal pro-brain natriuretic peptide...

Full description

Saved in:
Bibliographic Details
Published in:Rossiĭskiĭ kardiologicheskiĭ zhurnal Vol. 25; no. 12; p. 3948
Main Authors: Gareeva, D. F., Khamitova, A. F., Lakman, I. A., Ronzhin, R. P., Zulkarneev, R. Kh, Plotnikova, M. R., Tulbaev, E. L., Motlokh, L. D., Zagidullin, N. Sh
Format: Journal Article
Language:English
Russian
Published: FIRMA «SILICEA» LLC 30-12-2020
Subjects:
cardiovascular death
cardiovascular events
nt-probnp
pentraxin-3
risk stratification
sst2
stemi
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A multi-marker approach for assessing the prognosis of patients with ST-segment elevation myocardial infarction (STEMI) is a promising strategy.Aim. To assess the potential prognostic power of soluble growth stimulation gene-2 (sST2), pentraxin 3 (PTX3), and N-terminal pro-brain natriuretic peptide (NT-proBNP) in stratification of the risk of major cardiovascular events (CVE) during 2-year follow-up after STEMI.Material and methods. In 154 patients with STEMI, serum concentrations of NT-proBNP, sST2, and PTx-3 were determined upon admission to hospital. During the two-year follow-up period (734,2±61,2 days), correlation of biomarker concentrations with the risk of a composite endpoint (myocardial infarction + stroke + hospitalization due to cardiovascular disease + cardiovascular death) was analyzed.Results. In the 2-year follow-up, CVE were observed in 81 (55,1%) patients (CV death (n=33; 22,1%), recurrent MI (n=28; 18,.8%), stroke (n=8; 5,4%), hospitalization due to cardiovascular disease other than MI, stroke or cardiovascular death (n=12; 8,2%)). NT-proBNP (HR, 1,19; 95% CI, 1,018-1,32, p<0,001) and sST2 (HR, 1,000013; 95% CI, 1,00-1,001, p=0,007) correlated with CVE in contrast to PTX-3 (HR, 1,178; 95% CI, 0,798-1,73, p=0,434). The most accurate prediction of CVE was shown in the model with three biomarkers (AIC=831, BIC=843, LR=12,45, p=0,033). Conclusion. After STEMI, NT-proBNP and sST2, but not PTX-3, predicted CVE, while 3-marker analysis showed higher accuracy compared to single- and doublemarker.
ISSN:1560-4071
2618-7620
DOI:10.15829/1560-4071-2020-3948